Pascal Benderitter
Head of Medicinal Chemistry at QUANTRO Therapeutics GmbH | Mulhouse, Grand Est, France
Pascal Benderitter’s Email & Phone Number
VerifiedFree account · No credit card · 5 profiles/month
ContactOut Insights • AI Generated
Pascal Benderitter serves as Head of Medicinal Chemistry and Alliance Manager at QUANTRO Therapeutics GmbH, a biotechnology enterprise headquartered in Mulhouse, Grand Est, France. He completed his academic training at Université de Haute-Alsace Mulhouse-Colmar before assuming leadership of a research-focused venture founded as a corporate spin-off. His professional scope centers on engineering novel therapeutic candidates that utilize time-resolved RNA sequencing and comparative transcriptomics to block cancer-associated transcription factors.
BEST APPROACH TO REACH Pascal Benderitter
Reach out via LinkedIn with a concise pitch demonstrating how your platform directly accelerates comparative transcriptomics validation for early-stage transcription-targeted oncology pipelines.
Head of Medicinal Chemistry at QUANTRO Therapeutics GmbH in October 2023 - Present
Senior Program Director at Oncodesign Precision Medicine - OPM in September 2022 - September 2023
Senior Program Director at Oncodesign in May 2021 - September 2022
Discovery Program Director at Oncodesign in January 2013 - May 2021
Research Scientist at AC Immune in March 2009 - December 2012
Scientist - Postdoc at Johnson & Johnson Pharmaceutical Research and Development, a division of Janssen Pharmaceutica in February 2007 - February 2009
PhD student at Neuro3d in February 2004 - January 2007
PhD student at Faculté de pharmacie Strasbourg in January 2003 - December 2006
Research assistant at Morphochem AG in January 2002 - August 2002
Research assistant at Novartis Institutes for BioMedical Research in July 2001 - December 2001
Université de Haute-Alsace Mulhouse-Colmar, Master, October 2026
Ecole nationale supérieure de chimie, Master, October 1999 to October 2026
QUANTRO Therapeutics (“QUANTRO”) is a research-based entity that strives to discover and develop novel therapeutics interfering with disease-causing transcriptional programs in cancer and other diseases. QUANTRO will assemble a highly innovative drug-discovery pipeline that employs time-resolved RNA sequencing and comparative transcriptomics to identify and develop drug candidates interfering with transcriptional regulators. The first focus will be on cancer-associated transcription factors, which so far have been unamenable to pharmacologic intervention. QUANTRO was founded as a spin-off of the Institute of Molecular Biotechnology (“IMBA”) and the Research Institute of Molecular Pathology (“IMP”), both located in Vienna, Austria.
Discover more about QUANTRO Therapeutics GmbH
A new State of the Art in transcriptomic drug discovery: QUANTRO´s discovery platform makes "undruggable" Transcription Factors druggable by precise and time-resolved measure of functional transcriptional dynamics.
I am an experienced Biotech Entrepreneur and Executive with a proven track record as CEO, Member of the Board of Directors, and other senior leadership roles. Overall, I have gained more than 25 years’ leadership, development, research, and regulatory experience in the life ...
Head of R&D @QUANTRO Tx │ Drug discovery │ Oncology │ Transcriptomics
• Reporting directly to the CEO; building and leading a team of fifteen scientists.
• Established and industrialised new transcriptomic-based phenotypic screening platforms.
• Assay development
• Hit generation
• Hit-to-lead/Target Deconvolution
• Pharma amd CRO ...
Scientist Biology @QUANTRO Therapeutics GmbH | Science enthusiasts | Thinker | CRISPR & Targeted Genome Editing | Drug Discovery
Scientist Biology at QUANTRO Therapeutics GmbH
(Aug 2024 – Present)
Senior Scientist Biology at QUANTRO Therapeutics GmbH | Drug Discovery | PhD in Molecular (RNA) Biology
Drug Discovery of novel therapeutics targeting transcription factors in cancer
- Team Lead - High Throughput Screening
- Project Management
- CRO Management
- Automation
- Platform Development and Optimization
Fueling in-silico biology with scalable computational solutions | Sequencing hardware and software hacker | Supercharging screenable genomics and transcriptomics through AI
• Building and leading a multidisciplinary Computational Science team (Computer Science and Physics PhDs) with agile principles and SCRUM-inspired workflows to accelerate delivery and collaboration
• Establishing data analysis life cycles combining artifact tracking (QR c...
Scientist (Cancer) Biology at QUANTRO Therapeutics GmbH
We strive to establish a novel class of effective anti-tumor therapeutics that interfere with disease-causing transcriptional programs in cancer
What is Pascal Benderitter email address?
Email Pascal Benderitter at [email protected] and [email protected]. This email is the most updated Pascal Benderitter's email found in 2026.
What is Pascal Benderitter phone number?
Pascal Benderitter phone number is +33760933154.
How to contact Pascal Benderitter?
To contact Pascal Benderitter send an email to [email protected] or [email protected]. If you want to call Pascal Benderitter try calling on +33760933154. (updated on November 14, 2025)
What company does Pascal Benderitter work for?
Pascal Benderitter works for QUANTRO Therapeutics GmbH.
What is Pascal Benderitter's role at QUANTRO Therapeutics GmbH?
Pascal Benderitter is Head of Medicinal Chemistry
What industry does Pascal Benderitter work in?
Pascal Benderitter works in the Biotechnology industry.
